Written by Michael Duarte at NBC Los Angeles.com
It’s been a rough year for Los Angeles Dodgers relief pitcher Josh Ravin. After a family tragedy a year ago, Ravin broke his arm in a car accident during spring training. On Monday, Ravin received more bad news as he has been suspended by Major League Baseball for 80 games after he tested positive for a banned substance. Yahoo Sports was the first to report the news of the positive test and subsequent suspension.
Ravin becomes just the sixth player in 2016 to be suspended for a positive test for PED’s, following news earlier this week that Miami Marlins All-Star and former Dodger, Dee Gordon, tested positive for two banned substances in spring training. Ravin and Gordon join Toronto Blue Jays slugger Chris Colabello, Cleveland Indians center fielder Abraham Almonte, Philadelphia Phillies reliever Daniel Stumpf and New York Mets reliever Jenrry Mejia (who was banned for life) as the other players in baseball to test positive this year.
“We are disappointed to hear that Josh has violated Major League Baseball’s Joint Drug Prevention and Treatment Program,” the Dodgers said in a statement released on Monday. “The Dodgers fully support MLB’s policy toward eliminating performance enhancing substances from the sport and, as per the Joint Drug Program, we will have no further comment on this suspension.”
Ravin was currently on the Dodgers’ 40-man roster, but has been on the 60-day disabled list since the start of the season. He debuted with the Dodgers last year, and appeared in nine games, striking out 12 batters and posting an ERA of 6.75.
“During 2016 spring training, I came down with a severe case of intestinal flu and strep throat,” Ravin said Monday in his own statement. “I was put on antibiotics and lost a total of 20 pounds in less than seven days. To try and speed up my recovery, I took some supplements that I thought would help. Unfortunately, I was not as careful as I should have been and one of the supplements contained a banned substance.
To continue reading this article, click here.
